Mode
Text Size
Log in / Sign up
N/A N=68 Randomized Triple-blind Other

Light Therapy for Moderate Traumatic Brain Injury

Moderate Traumatic Brain Injury (TBI)

Enrolled (actual)
68
Serious AEs
18.6%
Results posted
Dec 2020
Primary outcome: Primary: Safety and Feasibility of Applying Light Therapy After Moderate TBI — 24; 19 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active LLLT helmet application (Device); Non-active LLLT helmet application (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Jul 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety and Feasibility of Applying Light Therapy After Moderate TBI
24; 19
SECONDARY
Neuroreactivity of Light Therapy to the Injured Brain Based on MRI Using the Fazekas Scale for Periventricular White Matter (PVWM)
19; 18; 3; 1; 1; 0
SECONDARY
Neuroreactivity of Light Therapy to the Injured Brain Based on MRI Using the Fazekas Scale for Deep White Matter (DWM)
19; 16; 3; 3; 1; 0
SECONDARY
Neuroreactivity of Light Therapy to the Injured Brain Based on Neurcognitive Function
4.55; 3.94; 12.64; 10.94; 17.18; 14.88

Summary

The purpose of this research study is to find out if a specialized helmet that provides low levels of near infrared light, also known as low-level light therapy (LLLT) has any effect on the recovery of people who have recently (within 72h) suffered a moderate traumatic brain injury (TBI).

Eligibility Criteria

Inclusion Criteria

  • At least 18 years old;
  • Injury within 72 hours at the time of consent;
  • Head injury requiring hospital admission;
  • A Glasgow Coma Scale (GCS) score of 9-12 or 13-15 with abnormal imaging.

Exclusion Criteria

  • Need for emergency neurosurgical intervention (including placement of intracranial pressure monitoring devices or drainage catheters);
  • Hemodynamic instability as determined by the clinician;
  • History of any of the following: (i) brain tumor; (ii) prior TBI occurring within the past year and requiring hospital admission; (iii) a new diagnosis within the past year of either stroke or epilepsy; (iv) an established diagnosis of any of the following neurodegenerative diseases: Alzheimer's, Picks, Parkinson's, Lewy body dementia, Huntington's, amytropic lateral sclerosis, spinocerebellar ataxia, vascular dementia, HIZ-associated dementia, dementia due to metabolic causes (Addison, Cushing, hypothyroidism, renal failure, prophyrias, Wilson, mitochondrial diseases, Wernicke-Korsakoff syndrome, and dementia of unknown etiology.
  • Pregnancy (all women of child-bearing age will need to have a negative pregnancy test prior to the start of the interventional portion of the study);
  • Electrical implants such as cardiac pacemakers or perfusion pumps;
  • Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants, or any other contra-indications to MRI.
  • Clinical determination that subject cannot undergo MRI
  • Breastfeeding
  • Unstable cervical fractures
  • Scalp lacerations or surgical wounds severe enough to preclude safe application of device
  • Unreliable to follow up
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02233413). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search